GuidelineJournal of hepato-biliary-pancreatic surgery2008
Guidelines for chemotherapy of biliary tract and ampullary carcinomas.
Guideline in Journal of hepato-biliary-pancreatic surgery, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival.Surgery today · 2017Pooled it
- Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: a systematic review.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2014Pooled it
- Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805).Cancer science · 2013Trial
- Efficacy and safety of FOLFOX for Japanese patients with advanced biliary tract cancer as second-line or later chemotherapy (JON2107-B study).International journal of clinical oncology · 2025Article
- Long-term oncologic benefit of postoperative chemotherapy in the resected ampulla of Vater cancer: hope or hype? A propensity score matching analysis.Annals of surgical treatment and research · 2025Article
- Advanced or metastatic biliary tract cancer in Japan: a study using the Japan Medical Data Center payer claims database.Journal of comparative effectiveness research · 2023Article
- Long-term (>5-year) survivors among unresectable or metastatic cancer patients treated with zoledronate-activated killer cells: Seven case reports.Clinical case reports · 2022Article
- Survival benefit of percutaneous transhepatic biliary drainage for malignant biliary tract obstruction-a prospective study comparing external and internal drainage techniques.Abdominal radiology (New York) · 2021Article
- Risk Stratification in Advanced Biliary Tract Cancer: Validation of the A.L.A.N. Score.Journal of oncology · 2020Article
- Germline mutations in cancer-predisposition genes in patients with biliary tract cancer.Oncotarget · 2019Article
- Article
- Preoperative platelet-lymphocyte ratio is an independent prognostic factor in ampullary carcinoma following pancreaticoduodenectomy.Oncology letters · 2018Article
- Progression of targeted therapy in advanced cholangiocarcinoma.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2015Review
- Actual status of clinical diagnosis in patients with primary gallbladder cancer associated with adenomyomatosis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2013Article
- Effect of biliary drainage on chemotherapy in patients with biliary tract cancer: an exploratory analysis of the BT22 study.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2012Article
- Adenocarcinoma of the ampulla of Vater: predictors of survival and recurrence after curative radical resection.Korean journal of hepato-biliary-pancreatic surgery · 2011Article
- Targeted therapy for biliary tract cancer.Cancers · 2011Article
- Article
- Surgery and chemotherapy for intrahepatic cholangiocarcinoma.World journal of hepatology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Few randomized controlled trials (RCTs) with large numbers of patients have been conducted to date in patients with biliary tract cancer, and standard chemotherapy has not been established yet. In this article we review previous studies and clinical trials regarding chemotherapy for unresectable biliary tract cancer, and we present guidelines for the appropriate use of chemotherapy in patients with biliary tract cancer. According to an RCT comparing chemotherapy and best supportive care for these patients, survival was significantly longer and quality of life was significantly better in the chemotherapy group than in the control group. Thus, chemotherapy for patients with biliary tract cancer seems to be a significant treatment of choice. However, chemotherapy for patients with biliary tract cancer should be indicated for those with unresectable, locally advanced disease or distant metastasis, or for those with recurrence after resection. That is why making the diagnosis of unresectable disease should be done with greatest care. As a rule, pathological diagnosis, including cytology or histopathological diagnosis, is preferable. Chemotherapy is recommended in patients with a good general condition, because in patients with general deterioration, such as those with a performance status of 2 or 3 or those with insufficient biliary decompression, the benefit of chemotherapy is limited. As chemotherapy for unresectable biliary tract cancer, the use of gemcitabine or tegafur/gimeracil/oteracil potassium is recommended. As postoperative adjuvant chemotherapy, no effective adjuvant therapy has been established at the present time. It is recommended that further clinical trials, especially large multi-institutional RCTs (phase III studies) using novel agents such as gemcitabine should be performed as soon as possible in order to establish a standard treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.